FORA Capital’s Sarepta Therapeutics SRPT Stock Holding History

FORA Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$699K	Buy	+32,157	New	+$622K	0.05%	275
2025 Q3	–	Sell	-93,189	Closed	-$1.59M	–	663
2025 Q2	$1.59M	Buy	93,189 +87,147	+1,442%	+$3.72M	0.18%	156
2025 Q1	$386K	Buy	+6,042	New	+$636K	0.04%	368
2023 Q3	–	Sell	-9,996	Closed	-$1.14M	–	576
2023 Q2	$1.14M	Buy	+9,996	New	+$1.29M	0.16%	145
2023 Q1	–	Sell	-13,376	Closed	-$1.73M	–	685
2022 Q4	$1.73M	Buy	13,376 +3,948	+42%	+$458K	0.28%	98
2022 Q3	$1.04M	Buy	9,428 +3,043	+48%	+$307K	0.2%	151
2022 Q2	$479K	Buy	+6,385	New	+$470K	0.1%	258
2022 Q1	–	Sell	-3,339	Closed	-$301K	–	628
2021 Q4	$301K	Buy	+3,339	New	+$285K	0.12%	222
2021 Q3	–	Sell	-7,373	Closed	-$573K	–	810
2021 Q2	$573K	Sell	7,373 -2,054	-22%	-$156K	0.11%	228
2021 Q1	$703K	Buy	9,427 +3,453	+58%	+$319K	0.23%	105
2020 Q4	$1.02M	Buy	+5,974	New	+$885K	0.16%	148
2020 Q3	–	Sell	-11,177	Closed	-$1.79M	–	962
2020 Q2	$1.79M	Buy	+11,177	New	+$1.52M	0.61%	28
2020 Q1	–	Sell	-9,698	Closed	-$1.25M	–	1319
2019 Q4	$1.25M	Buy	+9,698	New	+$979K	0.13%	217

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FORA Capital's SRPT Position: Q1 2026 in Review

FORA Capital opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 32,157 shares worth $699K. The stake represents 0.05% of the portfolio and ranks #275 among its holdings. This is a return to the name: FORA Capital previously reported a position in SRPT as recently as Q2 2025.

FORA Capital first reported a position in SRPT in Q4 2019 and has held it in 13 quarters since. The position peaked at $1.79M in Q2 2020. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

FORA Capital held 32,157 shares of Sarepta Therapeutics worth $699K as of Q1 2026.
Sarepta Therapeutics was a new FORA Capital position in Q1 2026.
Sarepta Therapeutics made up 0.05% of FORA Capital's portfolio in Q1 2026, its #275 holding.
FORA Capital first reported a position in Sarepta Therapeutics in Q4 2019 and has held it in 13 quarters since.
FORA Capital's Sarepta Therapeutics position peaked at $1.79M in Q2 2020.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.